Metastatic Prostate Cancer Market Report 2026

Metastatic Prostate Cancer Market Overview

• Metastatic Prostate Cancer market size has reached to $8.81 billion in 2025 • Expected to grow to $13.16 billion in 2030 at a compound annual growth rate (CAGR) of 8.3% • Growth Driver: Rising Demand For Personalized Treatments Enhancing Market Growth Due To Advances In Genomic Profiling And Biomarker Testing • Market Trend: Advancing Cancer Care with Targeted Radioligand Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Metastatic Prostate Cancer Market?

Metastatic prostate cancer is an advanced stage of prostate cancer in which cancer cells have spread from the prostate gland to other parts of the body, such as bones, lymph nodes, or distant organs. Its purpose is to indicate the progression of the disease beyond the prostate, guiding treatment decisions focused on slowing the spread, relieving symptoms, and improving survival. The main treatment types of metastatic prostate cancer include chemotherapy, immunotherapy, hormonal therapy, radiation therapy, and others. Chemotherapy uses strong drugs to kill fast-growing cells, including cancer cells. It is provided through various routes of administration, which include oral, parenteral, intravenous, intrathecal, intraperitoneal, intra-arterial, and topical. It is provided through different distribution channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others, and is used by various end users, including hospitals, clinics, cancer centers, research laboratories, and others.

What Is The Metastatic Prostate Cancer Market Growth Forecast?

The metastatic prostate cancer market size is expected to see strong growth in the next few years. It will grow to $13.16 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing development of novel immunotherapies, rising adoption of personalized cancer treatments, expansion of clinical trials for advanced therapies, growing use of radiopharmaceutical treatments, increasing focus on quality-of-life outcomes. Major trends in the forecast period include increasing adoption of targeted and hormonal therapies, rising use of combination treatment regimens, growing focus on precision oncology approaches, expansion of advanced diagnostic and biomarker testing, enhanced emphasis on patient-centered treatment strategies.

Global Metastatic Prostate Cancer Market Segmentation

1) By Treatment Type: Chemotherapy, Immunotherapy, Hormonal Therapy, Radiation Therapy, Other Treatments 2) By Route of Administration: Oral, Parenteral Route, Intravenous 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 4) By End User: Hospitals, Clinics, Cancer Centers, Research Laboratories, Other End-Users Subsegments: 1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens 2) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine Therapies 3) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors, Combined Androgen Blockade (CAB) 4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Body Radiotherapy (SBRT), Radiopharmaceutical Therapy, Intensity-Modulated Radiation Therapy (IMRT) 5) By Other Treatments: Targeted Therapy, Bone-Targeted Therapy, Clinical Trial Drugs, Palliative Therapy

What Is The Driver Of The Metastatic Prostate Cancer Market?

The rising demand for personalized treatments is expected to propel the growth of the metastatic prostate cancer market going forward. Personalized treatments refer to medical approaches tailored to an individual’s genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The rising demand for personalized treatments is due to the growing availability of genomic profiling and biomarker testing, as these technologies help identify specific mutations and biological markers, allowing clinicians to select therapies that are more likely to be effective for each individual. Personalized treatment approaches, such as biomarker-guided therapies and gene-targeted drugs, are transforming the way metastatic prostate cancer is managed by aligning specific therapies with each patient’s unique tumor profile to improve effectiveness and minimize side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023 compared to 6 in the year 2022. Therefore, the rising demand for personalized treatments is driving the growth of the metastatic prostate cancer industry.

Key Players In The Global Metastatic Prostate Cancer Market

Major companies operating in the metastatic prostate cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen Group, Exelixis Inc., Ferring Pharmaceuticals, Dendreon Pharmaceuticals LLC, Hinova Pharmaceuticals Inc., Janux Therapeutics Inc., Clarity Pharmaceuticals Ltd., Convergent Therapeutics Inc., Johnson & Johnson, Sanofi, Eli Lilly And Company, Roche Holding AG, Takeda Pharmaceutical Company Limited

Global Metastatic Prostate Cancer Market Trends and Insights

Major companies operating in the metastatic prostate cancer market are focusing on technological advancements in cancer treatment, such as advanced targeted radioligand technology to deliver precise radiation to cancer cells while sparing healthy tissue. Advanced targeted radioligand technology refers to a therapy combining a molecule targeting prostate specific membrane antigen PSMA with a radioactive isotope, allowing targeted destruction of cancer cells throughout the body. For instance, in March 2025, Novartis AG, a Switzerland based multinational pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Pluvicto for earlier use in patients with PSMA-positive metastatic castration-resistant prostate cancer. Pluvicto consists of a prostate-specific membrane antigen (PSMA), targeting ligand linked to a beta-emitting radionuclide; it functions by binding to PSMA-expressing tumor cells and delivering localized radiation to destroy cancer cells; unique features include high tumor specificity, favorable safety profile, and potential to be combined with other therapies; applications span advanced-stage prostate cancer treatment, particularly in patients who have progressed after androgen deprivation therapy; benefits include improved progression-free survival, targeted cytotoxicity, reduced off-target effects, and enhanced patient outcomes.

What Are Latest Mergers And Acquisitions In The Metastatic Prostate Cancer Market?

In June 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals for $2.4 billion. Through this acquisition, AstraZeneca aims to expand its next-generation radioconjugate platform and accelerate the development of targeted cancer therapies, particularly in metastatic castration-resistant prostate cancer and other solid tumors. Fusion Pharmaceuticals is a Canada-based clinical-stage company specializing in targeted therapies, including a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).

Regional Outlook

North America was the largest region in the metastatic prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Metastatic Prostate Cancer Market?

The metastatic prostate cancer market consists of sales of radiopharmaceuticals, biosimilars, cancer pain management drugs, diagnostic imaging agents, and supportive care medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Metastatic Prostate Cancer Market Report 2026?

The metastatic prostate cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic prostate cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.